<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We describe a patient who was treated with <z:chebi fb="0" ids="2663">amiodarone</z:chebi> for <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> based on arrhythmogenic right ventricular <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and who subsequently developed severe <z:chebi fb="0" ids="2663">amiodarone</z:chebi>-induced <z:e sem="disease" ids="C0040156" disease_type="Disease or Syndrome" abbrv="">thyrotoxicosis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Discontinuation of <z:chebi fb="0" ids="2663">amiodarone</z:chebi> resulted in sustained <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo>, which was successfully treated with a DC electrical shock, and subsequently <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo>, leading to <z:e sem="disease" ids="C0262935" disease_type="Disease or Syndrome" abbrv="">brain embolism</z:e> due to occlusion of the left middle cerebral artery </plain></SENT>
<SENT sid="2" pm="."><plain>Combination treatment with <z:chebi fb="0" ids="2663">amiodarone</z:chebi> and <z:chebi fb="2" ids="8378">prednisolone</z:chebi> was effective both in reducing the serum concentration of thyroid hormones and in improving the patient's general condition </plain></SENT>
<SENT sid="3" pm="."><plain>As the use of <z:chebi fb="0" ids="2663">amiodarone</z:chebi> becomes more widespread, treatment with <z:chebi fb="2" ids="8378">prednisolone</z:chebi> for this kind of <z:e sem="disease" ids="C0040156" disease_type="Disease or Syndrome" abbrv="">thyrotoxicosis</z:e>, which is resistant to conventional treatment, will be required increasingly frequently because <z:chebi fb="60" ids="24859">iodine</z:chebi> overload of the thyroid gland persists for some time after discontinuation of <z:chebi fb="0" ids="2663">amiodarone</z:chebi> treatment </plain></SENT>
</text></document>